~~<i id='27147B6ED9'><strike id='27147B6ED9'><tt id='27147B6ED9'><pre id='27147B6ED9'></pre></tt></strike></i>~~

Home» Wikipedia» explore

explore

author：hotspot 2025-09-28 22:40:15 Page View：17

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Delta passengers in Vegas fall sick while waiting on flight in triple
Next article： Psychedelics group wrestles with new pharma identity

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Stanford president’s abrupt resignation sparks debate

PeoplewalkontheStanfordUniversitycampusBenMargot/APAfterStanfordUniversitypresidentandprominentneuro

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Congressmen charge Covid hearing ‘could have been an email’

Rep.BradWenstrup(R-Ohio)AnnaMoneymaker/GettyImagesWASHINGTON—HouseRepublicanshaverepeatedlyaccusedBi